Previous Page  23 / 24 Next Page
Information
Show Menu
Previous Page 23 / 24 Next Page
Page Background

Page 98

Gastro 2016

August 11-12, 2016

Volume 6, Issue 4(Suppl)

J Gastrointest Dig Syst 2016

ISSN:2161-069X JGDS, an open access journal

conferenceseries

.com

August 11-12, 2016 Birmingham, UK

6

th

Global Gastroenterologists Meeting

Demographic profile and clinical presentation of ulcerative colitis in Trimurti hospital from

2007 to 2014

Patel Parag G, Chikhaliya Devraj P, Patel Rupal P

and

Mehta Kajri V

Trimurti Hospital,Gujrat, India

Backround:

There is paucity of clinical and demographic information of ulcerative colitis (UC) in rural area of Gujarat.

Objective:

To provide clinical and demographic data of UC patients.

Methods:

A review was performed in all cases of ulcerative colitis patients in the hospitals from 2007-2014 by retrieval from

medical record department. The diagnosis of UC was based on a combination of clinical, endoscopic and histological findings

consistent with UC. This study focused on food habits which included self identified food triggers and tobacco chewing. Along

with this extraintestinal manifestation were also taken into account. As the duration of study was quite long and data were

obtained by primary questionnaire and follow up. Patients were asked to come to hospital for filling up a questionnaire which

included their current disease condition tobacco chewing habits, smoking history food habits, presumed food triggers analysis

was performed using the Microsoft Excel and Graphpad prism.

Results:

A total of 47 patients with UC consulted over the 80 years study period (2007-2014). The mean annual incidence of

UC from 2007-2014 was 17.9 new cases: 100,000 new consults per year. An increase in the mean annual incidence from 9.9 in

2007-2010 to 25.9 in 2011-2014 was noted. 29.8% patients were chronic regular tobacco chewer, 2.1% were regular smokers

and 2.1% patient consumed alcohol regularly. There were 17% patients with family history of UC. Astonishing fact is that

none of the patient required surgical intervention and their symptoms are usually controlled by medicines therapy. None of

the patients had gut obstruction, massive intestinal bleed or toxic megacolon. Mean ESR compared for both the groups was

statistically significant.Weight loss and anemia were one of the key features of UC patients. Extraintestinal manifestation: 8.6%

had episcleritis, 23.4% patients had mouth ulcers, 2.1% patients had erythema nodusum and 17% (8) patients had complain

of hairfall and itching. 31.9% patients had pain while defecation and could not sit longer, who were later diagnosed with

sacroilitis. None of the patient had colingitis.

Conclusion:

The incidence of UC in our study is higher than Indian and other Asian country estimates but our rates may

be an overestimation of the true regional incidence since our hospital and associated centers are referral centers. Clinical

presentation is similar to neighboring state and countries except for higher appearance of extraintestinal symptoms and no

surgical intervention. Extensive research is required to understand food habits, tobacco chewing and reason or pattern of high

incidence of disease in this region.

drparag000@gmail.com

Nucleic acid polymers: Antiviral mechanisms and application in the treatment of chronic HBV and

HBV/HDV infection

Andrew Vaillant

Replicor Inc., Canada

N

ucleic acid polymers (NAPs) are a newly emerging antiviral technology for the treatment of chronic HBV infection and

HBV / HDV co-infection. NAPs have the unique ability to clear HBsAg from the blood of human patients, a critical

step in achieving a functional cure in HBV and HBV / HDV infection. Current mechanistic data underlying the basis for this

unique antiviral effect of NAPs as well as updated clinical data from trials using NAP-based combination therapy in patients

with chronic HBV infection and HBV / HDV co-infection will be presented.

availlant@replicor.com

J Gastrointest Dig Syst 2016, 6:4(Suppl)

http://dx.doi.org/10.4172/2161-069X.C1.035